HOUSTON, TX ― A vaccine showed potential to prevent relapse of KRAS-mutated pancreatic and colorectal cancers for patients who had previously undergone surgery, according to a Phase I trial led by researchers at The University of Texas MD Anderson Cancer Center. Results were published today in Nature Medicine. In the...
Latest News
This disease of colder months in temperate areas is practically non-existent in the U.S. due to an aggressive vaccination program for the past several decades. We currently see less than 5 cases of respiratory diphtheria annually. This dangerous respiratory disease is caused by a potent toxin produced by certain strains...
New York, NY – A new vaccine shows encouraging early results as a potential off-the-shelf treatment for certain patients with pancreatic or colorectal cancer, according to a study co-led by researchers at Memorial Sloan Kettering Cancer Center (MSK). The vaccine targets tumors with mutations (or changes) in the KRAS gene, a driving...
TOKYO & MUNICH & BASKING RIDGE, N.J. – New data from Daiichi Sankyo Company, Limited (hereafter, Daiichi Sankyo) for valemetostat, a potential first-in-class specific and potent dual inhibitor of EZH1 and EZH2, showed promising and durable tumor response in patients with relapsed/refractory peripheral T-cell lymphoma (PTCL) and adult T-cell leukemia/lymphoma...
A Valley boy diagnosed with a rare and fatal childhood disease is now being allowed access to an experimental drug. Denise and Rickey Miller’s 21-month-old son Woodrow has Niemann-Pick Disease Type C. It’s a form of childhood Alzheimer’s that eventually takes away the child’s ability to walk, talk, swallow, and breathe. For...
GRAND RAPIDS, Mich. (April 16, 2024) — A new study from Van Andel Institute scientists offers a first look into the complex molecular changes that occur in brain cells with Lewy bodies, which are key pathological hallmarks of Parkinson’s disease and some dementias. The findings, published in the journal Nature Communications, reveal...
WASHINGTON, DC — Vanda Pharmaceuticals Inc. (Nasdaq: VNDA) today announced that the U.S. Patent and Trademark Office has issued a notice of allowance for its PONVORY® (ponesimod) patent application, number 17/962,968, covering methods for reducing clinical management events before or during the treatment of multiple sclerosis and methods for reinitiating...
WASHINGTON, DC — Vanda Pharmaceuticals, Inc. today announced the publication of an article titled “The Efficacy of Tradipitant in Patients with Diabetic and Idiopathic Gastroparesis in Phase III Randomized Placebo-Controlled Clinical Trial” in the Clinical Gastroenterology and Hepatology Journal which follows a previously published study of tradipitant in the treatment...
WASHINGTON, DC — Vanda Pharmaceuticals, Inc. today announced the publication of an article titled “Efficacy and Safety of Iloperidone in Bipolar Mania: A Double-Blind, Placebo-Controlled Study” in the Journal of Clinical Psychiatry. The findings of this pivotal study have been submitted to the U.S. Food and Drug Administration (FDA) as...
WASHINGTON, DC — Vanda Pharmaceuticals, Inc., today announced that the U.S. Food and Drug Administration (FDA) has approved the Investigational New Drug (IND) application to evaluate VCA-894A for the treatment of a patient with Charcot-Marie-Tooth disease, axonal, type 2S (CMT2S), caused by cryptic splice site variants within the IGHMBP2 gene. CMT2S...